| Title: |
Prognostic significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in patients with myelofibrosis : a retrospective study |
| Authors: |
Koster, Kira-Lee; Messerich, Nora-Medea; Volken, Thomas; Cogliatti, Sergio; Lehmann, Thomas; Graf, Lukas; Holbro, Andreas; Benz, Rudolf; Demmer, Izadora; Jochum, Wolfram; Rao, Tata Nageswara; Silzle, Tobias |
| Source: |
ISSN:2072-6694 ; Cancers. |
| Publisher Information: |
MDPI |
| Publication Year: |
2023 |
| Collection: |
ZHAW digitalcollection (Repository of the Zurich University of Applied Sciences) |
| Subject Terms: |
Myelofibrosis; Prognostic system; Comorbidity; MDS-CI; DIPSS; MIPSS70; info:eu-repo/classification/ddc/616 |
| Description: |
In myelofibrosis, comorbidities (CMs) add prognostic information independently from the Dynamic International Prognostic Scoring System (DIPSS). The Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) offers a simple tool for CM assessment as it is calculable after having performed a careful history and physical examination, a small routine chemistry panel (including creatinine and liver enzymes) and a limited set of functional diagnostics. To assess the prognostic impact of the MDS-CI in addition to the DIPSS and the Mutation-Enhanced International Prognostic Scoring System (MIPSS)-70, we performed a retrospective chart review of 70 MF patients who had not received allogeneic stem cell transplantation (primary MF, n = 51; secondary MF, n = 19; median follow-up, 40 months) diagnosed at our institution between 2000 and 2020. Cardiac diseases (23/70) and solid tumors (12/70) were the most common CMs observed at MF diagnosis. Overall survival (OS) was significantly influenced by the MDS-CI (median OS MDS-CI low (n = 38): 101 months; MDS-CI intermediate (n = 25): 50 months; and high (n = 7): 8 months; p < 0.001). The MDS-CI added prognostic information after inclusion as a categorical variable in a multivariate model together with the dichotomized DIPSS or the dichotomized MIPSS70: MDS-CI high HR 14.64 (95% CI 4.42; 48.48), p = 0.0002, and MDS-CI intermediate HR 1.97 (95% CI 0.96; 4.03), p = 0.065, and MDS-CI high HR 19.65 (95% CI 4.71; 81.95), p < 0.001, and MDS-CI intermediate HR 1.063 (95% CI 0.65; 4.06), p = 0.2961, respectively. The analysis of our small and retrospective MF cohort suggests that the MDS-CI represents a useful tool to identify MF patients with an increased vulnerability due to comorbidities. However, analyses of larger cohorts are necessary to define the value of the MDS-CI as a prognostic tool in comparison with other comorbidity indices. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://doi.org/10.3390/cancers15194698; https://hdl.handle.net/11475/33528; https://digitalcollection.zhaw.ch/handle/11475/33528 |
| DOI: |
10.3390/cancers15194698 |
| DOI: |
10.21256/zhaw-33528 |
| Availability: |
https://hdl.handle.net/11475/33528; https://doi.org/10.3390/cancers15194698; https://doi.org/10.21256/zhaw-33528; https://digitalcollection.zhaw.ch/handle/11475/33528 |
| Rights: |
info:eu-repo/semantics/openAccess ; https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.DFC277A8 |
| Database: |
BASE |